Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard o...

Full description

Saved in:
Bibliographic Details
Main Authors: Aditi Singh, MBBS, MPH, Arthi Sridhar, MBBS, Aastha Poddar, MBBS, Anastasios Dimou, MD, Kaushal Parikh, MBBS, Mohamed Shanshal, MD, Anna Schwecke, APRN, CNP, MS, Nicole Moffett, APRN, CNP, MSN, Manish R. Patel, DO, Aaron S. Mansfield, MD, Konstantinos Leventakos, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
SCLC
EGFR
Osimertinib
Lurbinectedin
Tranformed SCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000232
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items